Annovis Bio(ANVS) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results Malvern, Pa., May 13, 2025 – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results. Forward-Looking Statements The first quarter was largely dedicated to the ini ...